Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.

This article was originally published in PharmAsia News

Executive Summary

Reata Pharmaceuticals on Jan. 7 licensed to Kyowa Hakko Kirin the Asian rights to its lead drug candidate, bardoxolone methyl, which a few years ago Reata re-directed from oncology to chronic kidney disease
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC073217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel